Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Uniqure Ord Shs (NQ: QURE ) 10.12 +3.45 (+51.72%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Uniqure Ord Shs < Previous 1 2 Next > uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease July 09, 2024 From uniQure Inc. Via GlobeNewswire uniQure Announces Sale of Commercial Manufacturing Facility to Genezen July 01, 2024 From uniQure Inc. Via GlobeNewswire uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease June 03, 2024 From uniQure Inc. Via GlobeNewswire uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress May 07, 2024 From uniQure Inc. Via GlobeNewswire uniQure Announces 2023 Financial Results and Highlights Recent Company Progress February 28, 2024 From uniQure Inc. Via GlobeNewswire uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease December 19, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 08, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease November 29, 2023 Patient enrollment expected to begin in first half of 2024 From uniQure Inc. Via GlobeNewswire uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress November 07, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting October 24, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs October 05, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 02, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy September 05, 2023 Clinical trial initiation expected in the fourth quarter of 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress August 01, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Leadership Addition to Support Advancement of Clinical Programs June 26, 2023 ~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~ From uniQure Inc. Via GlobeNewswire INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm June 22, 2023 From The Schall Law Firm Via Business Wire INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm June 21, 2023 From The Schall Law Firm Via Business Wire uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease June 21, 2023 From uniQure Inc. Via GlobeNewswire uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy June 20, 2023 Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring From uniQure Inc. Via GlobeNewswire uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 16, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million May 15, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress May 09, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting May 02, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 02, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 13, 2023 From uniQure Inc. Via GlobeNewswire uniQure to Participate in Multiple Upcoming Industry Conferences in March March 02, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces 2022 Financial Results and Highlights Recent Company Progress February 27, 2023 From uniQure Inc. Via GlobeNewswire uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb) February 23, 2023 From uniQure Inc. Via GlobeNewswire uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B February 21, 2023 From uniQure Inc. Via GlobeNewswire uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1 January 31, 2023 From uniQure Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.